Analysed AMPLIA THERAPEUTICS LTD (INNMF:OTCMKTS) News Sources
Amplia Therapeutics - Quarterly Activities and Cash Flow Reports - December 2025
30-01-2026
yahoo.com
Amplia Therapeutics Announces Opening of US Sites for Amplicity Pancreatic Cancer Trial
11-02-2026
yahoo.com
Amplia Therapeutics to Present at the Life Sciences Investor Forum on March 12th
11-03-2026
yahoo.com
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
13-03-2026
yahoo.com
Amplia flags key ACCENT milestone as 5 complete responses sharpen narmafotinib case in pancreatic cancer
23-03-2026
proactiveinvestors.com
Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial
23-03-2026
yahoo.com
We Think Amplia Therapeutics (ASX:ATX) Needs To Drive Business Growth Carefully
08-05-2026
yahoo.com
Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study
09-05-2026
yahoo.com
What is the current price of AMPLIA THERAPEUTICS LTD (INNMF:OTCMKTS)?
The current price of AMPLIA THERAPEUTICS LTD (INNMF:OTCMKTS) is $0.102.
AMPLIA THERAPEUTICS LTD (INNMF:OTCMKTS) absolute price change since previous trading day?
The absolute price change of AMPLIA THERAPEUTICS LTD (INNMF:OTCMKTS) since the previous trading day is $0.005.
AMPLIA THERAPEUTICS LTD (INNMF:OTCMKTS) percentage price change since previous trading day?
The percentage price change of AMPLIA THERAPEUTICS LTD (INNMF:OTCMKTS) since the previous trading day is 5.1546%.
What is the most recent average sentiment score for AMPLIA THERAPEUTICS LTD (INNMF:OTCMKTS)?
The most recent average sentiment score for AMPLIA THERAPEUTICS LTD (INNMF:OTCMKTS) is 80 out of 100.
What is the most recent average sentiment for AMPLIA THERAPEUTICS LTD (INNMF:OTCMKTS)?
The most recent sentiment for AMPLIA THERAPEUTICS LTD (INNMF:OTCMKTS) is .
SEC-8K** Filing Available For AMPLIA THERAPEUTICS LTD (INNMF:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.